Express for autoimmune diseases, Xinrui received $100 million to help develop a new generation of complement therapy

▎WuXi AppTec Content Team Editor Today, Dianthus Therapeutics announced the completion of a $100 million Series A financing, which will be used to expand the company’s team, advance its flagship project DNTH103 into the clinic, and accelerate the treatment of severe and rare autoimmune diseases.
Pipeline project development
.

DNTH103 is a next-generation monoclonal antibody that selectively targets the activated complement C1s protein
.

It may allow lower dose administration and less frequent subcutaneous injections
.

The complement cascade is part of the immune system that enhances the ability of antibodies and phagocytes to clear microorganisms and damaged cells, promote inflammation, and attack the cell membranes of pathogens
.

In many autoimmune diseases, however, the complement system malfunctions, causing or enhancing an attack on one's own tissues
.

Currently, a number of therapies targeting different targets in the complement cascade have been approved for marketing or are in clinical development
.

Dianthus' goal is to increase the selectivity of monoclonal antibodies for the complement pathway, potentially overcoming the limitations of existing complement therapies
.

Current antibody therapies bind complement proteins in an inactive and activated state
.

Antibodies that bind to an inactive complement protein do not achieve the effect of inhibiting the activity of the protein, resulting in the need for larger doses to achieve the goal of inhibiting the activity of the complement protein
.

The company's DNTH103 selectively binds to the activated complement C1s protein, which allows it to treat patients at lower doses and at longer dosing intervals
.

And half-life extension technology can further reduce the frequency of patients receiving treatment
.

DNTH103 is designed to alleviate the inconvenience of frequent intravenous infusions or subcutaneous large doses of drugs, expanding the patient population who can benefit from complement therapy
.

▲Dianthus' R&D pipeline (Image source: Dianthus' official website) "We are committed to improving the lives of patients with severe and rare autoimmune diseases and are convinced that our selective antibodies have the potential to be a 'best-in-class' therapy
.

" said Mr.
Marino Garcia, President and CEO of Dianthus therapeutics
.

Reference: [1] Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases.
Retrieved May 3, 2022, from https:// -launches-with-100m-to-develop-selective-antibody-complement-therapeutics-to-treat-severe-and-rare-autoimmune-diseases-301537293.
htmlDisclaimer: WuXi AppTec content team focuses on global biomedical health Research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.